Socio-Demographic, Biological, and Therapeutic Characteristics of People Living with HIV under Care at the Outpatient Treatment Center in Pointe-Noire, Republic of the Congo
HIV infection remains a major public health problem in sub-Saharan Africa. The current challenge remains screening and access to treatment. This study aimed to describe the sociodemographic, therapeutic, and biological characteristics of HIV patients followed at the Pointe-Noire outpatient treatment center. This was a descriptive cross-sectional study conducted from September to December 2025 among 150 patients. Data were obtained from medical records and questionnaires. The population was predominantly female (72.7%) and young (20 to 39 years old), with a mean age of 36.11 ± 9.8 years, extremitie ranging from 20 to over 50 years. Unmarried patients accounted for 84.0% of cases, and 56.7% had tattoos; 47.33% had a primary school education, and 46.01% had a secondary school education. The majority of patients (92.0%) were receiving antiretroviral therapy. TDF + 3TC + DTG was the primary treatment regimen used by 45.7% of the subjects. Virologic monitoring was well maintained, with over 76.0% of patients having a CD4 count ≥ 500 cells/μL and 72.0% having an undetectable viral load. The virologic profile observed in our patients indicated good immunovirologic status.
References
[1]
UNAIDS (2023) Global HIV & AIDS statistics—2023 Fact Sheet. UNAIDS.
[2]
World Health Organization (WHO) (2022) Consolidated Guidelines on HIV, Viral Hepatitis and STI Prevention, Diagnosis, Treatment and Care.
[3]
World Health Organization (WHO) (2021) Update of Recommendations on First-and Second-Line Antiretroviral Regimens.
[4]
European AIDS Clinical Society (EACS) (2023) Guidelines Version 12.0.
[5]
Bigna, J.J.R. and Noubiap, J.J.N. (2021) Determinants of Immunological Non-Response in HIV-Infected Adults Receiving Antiretroviral Therapy. PLOS ONE, 16, e0252020.
[6]
Bahemana, E., Esber, A., Dear, N., Ganesan, K., et al. (2020) Impact of Age on CD4 Recovery and Viral Suppression over Time among Adults Living with HIV Who Initiated Antiretroviral Therapy in the African Cohort Study. AIDS Research and Therapy, 17, Article 66.
[7]
Edmonds, A., Brazier, E., Musick, B.S., Yotebieng, M., Humphrey, J., Abuogi, L.L., etal. (2022) Clinical and Programmatic Outcomes of HIV-Exposed Infants Enrolled in Care at Geographically Diverse Clinics, 1997–2021: A Cohort Study. PLOS Medicine, 19, e1004089. https://doi.org/10.1371/journal.pmed.1004089
[8]
Romo, M.L., Brazier, E., Mahambou-Nsondé, D., De Waal, R., Sekaggya-Wiltshire, C., Chimbetete, C., et al. (2022) Real-World Use and Outcomes of Dolutegravir-Containing Antiretroviral Therapy in HIV and Tuberculosis Co-Infection: A Site Survey and Cohort Study in Sub-Saharan Africa. Journal of the International AIDS Society, 25, e25961. https://doi.org/10.1002/jia2.25961
[9]
Rodger, A.J., Cambiano, V., Bruun, T., Vernazza, P., et al. (2019) The Lancet, 393, 2428-2438. https://doi.org/10.1016/s0140-6736(19)30418-0
[10]
Gandhi, R.T., Landovitz, R.J., Sax, P.E., Smith, D.M., Springer, S.A., Günthard, H.F., et al. (2025) Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel. Journal of the American Medical Association, 333, 609-628. https://doi.org/10.1001/jama.2024.24543
[11]
Ndziessi, G., Aloumba, A.J., Essie, D.E.M., Niama, A.C., Mbele, F.G., Diafouka, M., et al. (2020) Factors Associated with Antiretroviral Treatments Failure among HIV-Positive Patients in Congo: A Retrospective Cohort Study. World Journal of AIDS, 10, 201-214. https://doi.org/10.4236/wja.2020.104018
[12]
Adedimeji, A.A., Hoover, D.R., Shi, Q.H., etal. (2020) Trends in Demographic and Clinical Characteristics of Patients Enrolled in HIV Care and Subsequent Antiretroviral Therapy Initiation in the Central Africa International Epidemiology Databases to Evaluate AIDS (CA-IeDEA) Adult Cohort 2004–2018. https://doi.org/10.1101/2020.07.17.20156141
[13]
Trickey, A., Stone, J. and Vickerman, P. (2023) Eliminating HIV in the UK among Men Who Have Sex with Men. The Lancet HIV, 10, e695-e696. https://doi.org/10.1016/s2352-3018(23)00239-4
[14]
Kharsany, A.B.M. and Karim, Q.A. (2016) HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities. The Open AIDS Journal, 10, 34-48. https://doi.org/10.2174/1874613601610010034
[15]
Bvochora, T., Satyanarayana, S., Takarinda, K.C., Bara, H., Chonzi, P., Komtenza, B., et al. (2019) Enhanced Adherence Counselling and Viral Load Suppression in HIV Seropositive Patients with an Initial High Viral Load in Harare, Zimbabwe: Operational Issues. PLOS ONE, 14, e0211326. https://doi.org/10.1371/journal.pone.0211326
[16]
Yosef, T., Wondimu, W., Nigussie, T., Asefa, A., Qanche, Q., Mekonnen, B., et al. (2022) Factors Associated with HIV Preventive Behavior among Adults in Majang Zone of Gambella Region, Southwest Ethiopia. Frontiers in Medicine, 9, Article 807730. https://doi.org/10.3389/fmed.2022.807730
[17]
Tolmay, J., Knight, L., Muvhango, L., Polzer-Ngwato, T., St？ckl, H. and Ranganathan, M. (2022) Women’s Economic Contribution, Relationship Status and Risky Sexual Behaviours: A Cross-Sectional Analysis from a Microfinance-Plus Programme in Rural South Africa. AIDS and Behavior, 26, 2349-2362. https://doi.org/10.1007/s10461-021-03566-5
[18]
Elenga Ike, A.M., Mfoutou Mapanguy, C.C., Vouvoungui, J.C., Mouzinga, F.H., Miguel, L.M., Oyaba Molenga, E.P., et al. (2026) Epidemiological Characteristics of People Living with HIV on Antiretroviral Therapy (ART) in Pointe-Noire, Republic of Congo. BMC Infectious Diseases, 26, Article No. 279. https://doi.org/10.1186/s12879-025-12178-6
[19]
Degenhardt, L., Webb, P., Colledge-Frisby, S., Ireland, J., Wheeler, A., Ottaviano, S., et al. (2023) Epidemiology of Injecting Drug Use, Prevalence of Injecting-Related Harm, and Exposure to Behavioural and Environmental Risks among People Who Inject Drugs: A Systematic Review. The Lancet Global Health, 11, e659-e672. https://doi.org/10.1016/s2214-109x(23)00057-8
[20]
Dorward, J., Sookrajh, Y., Khubone, T., van der Molen, J., Govender, R., Phakathi, S., et al. (2023) Implementation and Outcomes of Dolutegravir-Based First-Line Antiretroviral Therapy for People with HIV in South Africa: A Retrospective Cohort Study. The Lancet HIV, 10, e284-e294. https://doi.org/10.1016/s2352-3018(23)00047-4
[21]
Phillips, A., Shroufi, A., Vojnov, L., Cohn, J., Roberts, T., Ellman, T., et al. (2022) Progress toward Viral Suppression among People Living with HIV in Sub-Saharan Africa. BMC Public Health, 22, Article No. 1203.
[22]
Kerschberger, B., Boulle, A., Kuwengwa, R., Ciglenecki, I., Schomaker, M., et al. (2022) Virological Suppression among Adults Receiving Antiretroviral Therapy in African Cohorts. BMJ Open, 12, e054019.
[23]
Siedner, M.J., Ng, C.K., Bassett, I.V., Katz, I.T., Bangsberg, D.R. and Tsai, A.C. (2015) Trends in CD4 Count at Presentation to Care and Treatment Initiation in Sub-Saharan Africa, 2002–2013: A Meta-Analysis. Clinical Infectious Diseases, 60, 1120-1127. https://doi.org/10.1093/cid/ciu1137
[24]
Venter, W.D.F., Moorhouse, M., Sokhela, S., Fairlie, L., Mashabane, N., Masenya, M., et al. (2019) Dolutegravir Plus Two Different Prodrugs of Tenofovir to Treat HIV. New England Journal of Medicine, 381, 803-815. https://doi.org/10.1056/nejmoa1902824
[25]
Kamangu, E.N., Bulanda, B.I., Mwanaut, I.M., Makoka, S.K. and Mesia, G.K. (2021) Evaluation of Rational Use of Antiretrovirals before the Dolutegravir Transition in Kinshasa, Democratic Republic of Congo. World Journal of AIDS, 11, 41-49. https://doi.org/10.4236/wja.2021.112004
